BioTuesdays

Category - Markets

Profound Medical Logo
Markets

CIBC starts Profound Medical at OP, PT $3.50

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15. Analyst Prakash Gowd...

November 16, 2017
Mirati Therapeutics
Markets

Leerink ups Mirati Therapeutics OP; PT $20

Leering upgraded Mirati Therapeutics (NASDAQ:MRTX) to “outperform” from “market perform” and raised its price target to $20 from $15, after the company re-prioritized its pipeline programs. The stock closed at $15.50 on...

November 14, 2017
GTX
Markets

Stifel starts GTx at buy; PT $16

Stifel initiated coverage of GTx (NASDAQ:GTXI) a “buy” rating and $16 price target. The stock closed at $7.51 on Nov. 8. “We believe the Street is overlooking blockbuster potential for lead pipeline asset, enobosarm, in...

November 9, 2017
IRIDEX
Markets

Roth resumes coverage of IRIDEX at buy, PT $13

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter. “Further, the...

November 3, 2017
Syros-Logo
Markets

Roth starts Syros at neutral, PT $16

Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23. “Syros is maturing into a solid company, but value...

October 24, 2017
Markets

Roth resumes coverage of Actinium at buy, PT $6

Roth Capital Partners resumed coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with a “buy” rating and price target of $6.  The stock closed at 73 cents on Oct.23. Analyst Jotin Marango writes that Actinium...

October 24, 2017
GlycoMimetics
Markets

Roth starts GlycoMimetics at buy, PT $25

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...

October 24, 2017
Appili Therapeutics
Markets

Appili Therapeutics closes private placement

Closely-held Appili Therapeutics raised $3,062,000 in a private placement, bringing the total equity raised since its seed round in March 2016 to $7.5-million. The private placement includes investments from new and...

October 23, 2017